Key result
Fixed combinations of enalapril and diltiazem ER reduced trough sitting diastolic blood pressure by 7.6 and 8.3 mm Hg versus monotherapies.
Why the study?
Does a fixed combination of enalapril and diltiazem ER reduce blood pressure more effectively than their monotherapies or placebo in patients with stage 1 to 3 essential hypertension?
RCT (n=891)
Double-blind
randomized
Yes
Does a fixed combination of enalapril and diltiazem ER reduce blood pressure more effectively than their monotherapies or placebo in patients with stage 1 to 3 essential hypertension?
Fixed combinations of enalapril and diltiazem ER provide greater blood pressure lowering efficacy than their individual components in patients with stage 1 to 3 hypertension, with a similar tolerability profile.
Answers are grounded in this paper and cite their sources.
Supports fixed enalapril-diltiazem ER combinations in stage 1-3 hypertension; extends RCT evidence for combination over monotherapy.
The safety and efficacy of two fixed dose combinations of enalapril and diltiazem extended release formation (ER) (E/D) were compared with their monotherapies and placebo in patients with stage 1 to 3 hypertension. The trial design was a multicenter, randomized, double blind, placebo controlled, parallel group, 12 week treatment phase, followed by a 36 week, open label phase. A total of 891 patients with sitting diastolic blood pressure (SiDBP) between 95 and 115 mm Hg were randomly assigned to enalapril 5 mg, diltiazem ER 120 mg, diltiazem ER 180 mg, enalapril 5 mg/diltiazem ER 120 mg (E5/D120), enalapril 5 mg/ diltiazem ER 180 mg (E5/D180), or placebo. In the open label phase, 562 patients received the fixed combination, titrated as needed to control SiDBP < 90 mm Hg. Efficacy was determined with trough (24 +/- 2 h postdose) sitting blood pressure measurements at week 12 and at the end of the open label part of the study. Safety was evaluated based on patient symptoms, clinical laboratories, and electrocardiograms (ECG). E5/D120 and E5/D180 significantly reduced trough SiDBP (-7.6 and -8.3 mm Hg, respectively; P < .05) versus their monotherapies. E5/D120 and E5/D180 significantly reduced trough sitting systolic blood pressure (-7.9 and -9.0, respectively; P < .05) versus both diltiazem ER monotherapies. All active treatments significantly decreased SiDBP and SiSBP versus placebo. E/D effectively lowered SiDBP and SiSBP during the open label extension. No significant difference was seen among treatment groups for the overall incidence of adverse events. The most common drug related adverse events were headache, edema/swelling, dizziness, asthenia/fatigue, cough, rash, and impotence. The event frequency for the combinations were similar to those seen with the monotherapies. Fixed combinations of E/D were generally well tolerated, with an increased blood pressure lowering effect as compared with the individual components in patients with stage I to III hypertension.
No takes yet. Share an insight, caveat, or question.
William C. Cushman (1998) conducted an RCT in Stage 1 to 3 essential hypertension (n=891). Fixed combination of enalapril and diltiazem ER vs. Enalapril 5 mg, diltiazem ER 120 mg, diltiazem ER 180 mg, or placebo was evaluated on Trough sitting diastolic blood pressure at week 12 (MD -7.6 and -8.3 mm Hg, p=< .05). Fixed combinations of enalapril and diltiazem ER reduced trough sitting diastolic blood pressure by 7.6 and 8.3 mm Hg versus monotherapies.
Synapse has enriched 10 related papers. Consider them for comparative context: